Though the PIKfyve inhibitor Apilimod has been shown to decrease SARS-CoV-2 infection in cell culture by blocking viral content release from endosomes and is currently being considered as a COVID-19 therapeutic in a Phase II clinical trial (listed as recruiting patients, NCT04446377), efficacy in COVID-19 animal models has yet to be reported22,23. The gene discussed is PIKFYVE; the disease is COVID-19.